A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma

Adenocarcinoma (AC) and squamous cell carcinoma (SCC), sub-types of non-small cell lung cancer (NSCLC), both present unique features at the genome, epigenome, transcriptome and proteome levels, as well as shared clinical and histopathological characteristics, but differ in terms of treatment. To ensure proper treatment, one must be able to distinguish between these sub-types. Here, we identify novel biomarker proteins in NSCLC, allowing for distinguishing between the AC and SCC sub-types. Proteomics analysis distinguished between healthy and tumor tissues, with the expression level of 1,494 proteins being altered, 378 of which showed a ≥|100|-fold change. Enrichment of proteins related to protein synthesis and degradation, and of proteins associated with mitochondria, metabolism, and apoptosis, was found. Network analysis defined groups of proteins, such as those associated with cell metabolic processes or with fatty acid/lipid metabolism and transport. Several biomarkers that enable for distinguishing between AC and SCC were identified here for the first time, and together with previous reports confirmed here, led us to propose a list of proteins differentially expressed in SCC and AC. Some of these biomarkers are clear signatures for AC or SCC and four of them are secreted proteins. The presence of the mitochondrial protein SMAC/Diablo in the nucleus was found to be a signature for SCC. Precise diagnosis of AC and SCC is essential for selecting appropriate treatment and thus, increasing patient life expectancy. Finally, the search for drugs that target some of these biomarkers may lead to new treatments for lung cancer.

[1]  P. Pedersen,et al.  Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells. , 1984, Cancer research.

[2]  P. Hogg,et al.  Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase , 2000, Nature.

[3]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[4]  M. Hunt,et al.  Characterization of an Acyl-CoA Thioesterase That Functions as a Major Regulator of Peroxisomal Lipid Metabolism* , 2002, The Journal of Biological Chemistry.

[5]  A. Kubo,et al.  Expression of thyroid transcription factor-1 in 16 human lung cancer cell lines. , 2003, Lung cancer.

[6]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[7]  J. Jenkins,et al.  Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[9]  J. Vockley,et al.  Structures of Isobutyryl-CoA Dehydrogenase and Enzyme-Product Complex , 2004, Journal of Biological Chemistry.

[10]  S. Bao,et al.  Relationship between expression of Smac and Survivin and apoptosis of primary hepatocellular carcinoma. , 2006, Hepatobiliary & pancreatic diseases international : HBPD INT.

[11]  J. Meléndez-Zajgla,et al.  High Smac/DIABLO expression is associated with early local recurrence of cervical cancer , 2006, BMC Cancer.

[12]  Y. Yatabe,et al.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.

[13]  Martin Schostak,et al.  Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value , 2008, Journal of Cancer Research and Clinical Oncology.

[14]  C. Mahotka,et al.  Disturbed Expression of the Apoptosis Regulators XIAP, XAF1, and Smac/DIABLO in Gastric Adenocarcinomas , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[15]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[16]  A. Chinnaiyan,et al.  AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  R. Herbst,et al.  Multitargeted inhibitors in lung cancer: new clinical data. , 2008, Clinical lung cancer.

[18]  G A Colditz,et al.  Comparison of aspects of smoking among the four histological types of lung cancer , 2008, Tobacco Control.

[19]  Z. Qian,et al.  Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen , 2009, BMC Cancer.

[20]  M. Tainsky,et al.  Genomic and proteomic biomarkers for cancer: a multitude of opportunities. , 2009, Biochimica et biophysica acta.

[21]  Shui-Tein Chen,et al.  Proteomics analysis of A375 human malignant melanoma cells in response to arbutin treatment. , 2009, Biochimica et biophysica acta.

[22]  T. Fan,et al.  Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM) , 2009, Molecular Cancer.

[23]  R. Lewensohn,et al.  Use of narrow‐range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion , 2009, Proteomics.

[24]  R. Kurzrock,et al.  Targeted therapy in non-small-cell lung cancer—is it becoming a reality? , 2010, Nature Reviews Clinical Oncology.

[25]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[26]  Saroj P. Mathupala,et al.  The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. , 2010, Biochimica et biophysica acta.

[27]  J. Lemasters,et al.  Free tubulin modulates mitochondrial membrane potential in cancer cells. , 2010, Cancer research.

[28]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[29]  C. Dang,et al.  Therapeutic targeting of cancer cell metabolism , 2011, Journal of Molecular Medicine.

[30]  I. Sevrioukova.  Apoptosis-inducing factor: structure, function, and redox regulation. , 2011, Antioxidants & redox signaling.

[31]  William C Hahn,et al.  Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. , 2011, Cancer discovery.

[32]  Richard W Tothill,et al.  Next-generation sequencing for cancer diagnostics: a practical perspective. , 2011, The Clinical biochemist. Reviews.

[33]  Puthen V. Jithesh,et al.  Gene Expression Meta-Analysis Identifies VDAC1 as a Predictor of Poor Outcome in Early Stage Non-Small Cell Lung Cancer , 2011, PloS one.

[34]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[35]  Junji Yoshida,et al.  Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal? , 2012, Japanese journal of clinical oncology.

[36]  S. Qin,et al.  Smac: Its role in apoptosis induction and use in lung cancer diagnosis and treatment. , 2012, Cancer letters.

[37]  Xiaoguang Sun,et al.  Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy , 2013, IUBMB life.

[38]  M. J. Kim,et al.  Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. , 2013, Annals of diagnostic pathology.

[39]  V. Shoshan-Barmatz,et al.  Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo , 2014, Molecular therapy. Nucleic acids.

[40]  Yunfeng Zhao,et al.  Components of cancer metabolism and therapeutic interventions. , 2014, Mitochondrion.

[41]  Joshua J. Steffan,et al.  Supporting a Role for the GTPase Rab7 in Prostate Cancer Progression , 2014, PloS one.

[42]  Juancarlos Chan,et al.  Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..

[43]  M. Scott,et al.  Multiple Surface Regions on the Niemann-Pick C2 Protein Facilitate Intracellular Cholesterol Transport* , 2015, The Journal of Biological Chemistry.

[44]  W. Dempke,et al.  Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment? , 2015, Translational lung cancer research.

[45]  V. Shoshan-Barmatz,et al.  The mitochondrial voltage-dependent anion channel 1 in tumor cells. , 2015, Biochimica et biophysica acta.

[46]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[47]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[48]  K. Aldape,et al.  Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. , 2016, Molecular cell.

[49]  Genetic polymorphisms in glycolytic pathway are associated with the prognosis of patients with early stage non-small cell lung cancer , 2016, Scientific reports.

[50]  M. Zakowski,et al.  Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens. , 2016, Archives of pathology & laboratory medicine.

[51]  Matthew G. Vander Heiden,et al.  Understanding the Intersections between Metabolism and Cancer Biology , 2017, Cell.

[52]  B. Vogelstein,et al.  Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention , 2017, Science.